Meeting
2012 ASCO Annual Meeting
The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS).
Authors
Julia C. Chisholm
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Julia C. Chisholm , Michela Casanova , Johannes H. Merks , Birgit Geoerger , Raphael F. Rousseau , Nicola Moore , Christophe Dhalluin , Odile Oberlin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT00643565
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS9597^)
Abstract #
TPS9597^
Poster Bd #
46B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
BERNIE: Open-label, randomized, phase II study of bevacizumab plus chemotherapy in pediatric metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).
First Author: Julia C. Chisholm
Poster
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
First Author: Michael W. Bishop
Poster
2022 ASCO Annual Meeting
Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.
First Author: Danielle Klingberg
Poster
2019 ASCO Annual Meeting
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
First Author: Christine Mauz-Körholz